FDA Rejects Replimune Melanoma Therapy, Citing Data Concerns
Replimune Group has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration for its Biologics License Application (BLA) seeking approval of RP1 in…
Read More...
Read More...
